Lumosa Therapeutics Co., Ltd. (TPEX: 6535)

Market Cap	40.74B
Revenue (ttm)	47.71M
Net Income (ttm)	-280.72M
Shares Out	164.93M
EPS (ttm)	-1.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	341,671
Open	249.00
Previous Close	248.00
Day's Range	243.00 - 250.50
52-Week Range	58.70 - 269.50
Beta	0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. L...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 47
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6535

Financial Performance

In 2023, Lumosa Therapeutics's revenue was 56.92 million, an increase of 113.63% compared to the previous year's 26.64 million. Losses were -238.04 million, -51.88% less than in 2022.